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ABSTRACT. Fabry disease (FD) is an X-linked inborn error of metabolism 
caused by alpha-galactosidase A deficiency. The Fabry Registry is an 
ongoing observational database that compiles clinical data on patients with 
FD. We analyzed the Fabry Registry data of patients enrolled in Brazil 
to characterize the demographic and baseline clinical characteristics of 
this patient population. As of October 2010, 126 Brazilian patients were 
enrolled in the Registry (61 males, 65 females). The median age at onset 
of symptoms in males was 9.8 years, compared to 11.4 years in females. 
Males were diagnosed at a median age of 31.9 years and females at 27.1 
years. The median time between the onset of first symptoms and diagnosis 
was 20.3 years in males and 14.3 years in females. Neurologic pain was 
the presenting symptom most frequently reported by both genders. Renal 
events were the most common clinical events reported in males, while 
cardiac events were the most common events in females. The results of 
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these analyses indicate that Brazilian patients were frequently not diagnosed 
with FD until many years after the onset of symptoms. Many Brazilian 
Fabry Registry patients report experiencing neurological pain, and many 
Brazilian women with FD exhibit substantial signs and symptoms. The 
prevalence of neurological pain as a presenting symptom among Brazilian 
Registry patients is consistent with previous reports from the overall 
Registry population. FD is treatable, and earlier diagnosis will allow for 
prompt initiation of appropriate treatment that may avert irreversible 
damage that could occur during the time from symptom onset to diagnosis. 
Key words: Fabry disease; Alpha-galactosidase A deficiency;
Fabry Registry; Brazil; Demographics
INTRODUCTION
Fabry disease (FD) is an X-linked inborn error of metabolism caused by a deficiency of 
the lysosomal enzyme alpha-galactosidase A (Desnick et al., 2001). The disease process starts in 
infancy, although the majority of patients remain clinically asymptomatic during the very first 
years of life. The first clinical symptoms, including neuropathic pain in the extremities, hypohi-
drosis, and gastrointestinal symptoms such as abdominal pain, diarrhea, and food intolerance, 
typically appear between the ages of 3 and 10 years, with presentation in girls being reported a 
few years later than that in boys (Hopkin et al., 2008; Wilcox et al., 2008). As individuals with 
FD age, the accumulation of globotriaosylceramide results in progressive damage to vital organ 
systems, organ failure, and subsequently, a shortened life expectancy due to end-stage renal dis-
ease and life-threatening cardiovascular or cerebrovascular complications (Branton et al., 2002; 
Mehta et al., 2004; Schiffmann et al., 2009; Sims et al., 2009). FD has long been regarded as an 
adult disease primarily affecting males, while it was believed that female patients were simply 
carriers who were protected against development of the disease symptoms and events. However, 
evolving knowledge about the natural history of the disease suggests that a high percentage of 
female patients develop vital organ involvement, including that of the kidneys, heart, and/or 
brain, albeit approximately a decade later than males (Wilcox et al., 2008).
There are many variations in the clinical manifestations of FD among individual pa-
tients regardless of gender, and there may also be important differences in the clinical manifes-
tations of patients residing in different regions of the world. In the present report, we analyzed 
Fabry Registry data from patients enrolled in Brazil to characterize the demographic and base-
line clinical characteristics of this patient population. The Fabry Registry (www.fabryregistry.
com) is an international observational voluntary program initiated in 2001. It is a global out-
comes assessment and disease management program that compiles patient outcome data from 
routine clinical practice to provide the medical community with resources to help optimize 
patient care. The primary objectives of the Fabry Registry are to enhance understanding of the 
variability, progression, and natural history of FD, including of heterozygous females with the 
disease; to assist the Fabry medical community with the development of recommendations for 
monitoring patients and reports on patient outcomes to help optimize patient care; to charac-
terize and describe the Fabry population as a whole, and to evaluate the long-term safety and 
effectiveness of treatment. 
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MATERIAL AND METHODS
The Fabry Registry is an ongoing observational database that compiles clinical and 
investigative data on patients with FD. It is sponsored and administered by Genzyme, a 
Sanofi company (Cambridge, MA, USA). The Fabry Registry is the largest global assess-
ment program designed to collect clinical data related to the onset and progression of FD. 
All FD patients are eligible to enroll in the Registry regardless of symptoms or reception 
of enzyme replacement therapy (ERT). Patient and physician participation is voluntary. All 
patients provide informed consent through a process approved by local Institutional Review 
Boards/Ethics Committees. 
Treating physicians determine the actual frequency of assessments according to pa-
tients’ individualized needs, although the Fabry Registry provides participating physicians 
with a recommended schedule of assessments. Given the voluntary nature of the data report-
ing, patients’ ages at clinical assessments and time intervals between assessments are variable. 
Data collected by physicians or their designees are submitted to the Fabry Registry for central 
processing through a set of standardized electronic case report forms. 
In the present analyses, we characterized Brazilian Fabry Registry patients accord-
ing to baseline demographics and the occurrence of clinical events. Only natural history data 
(i.e., obtained from untreated patients receiving ERT or prior to treatment with ERT) were 
included. Patients for whom ERT status was unknown were excluded from the analyses to 
ensure that clinical events occurred prior to initiation of ERT. Significant clinical events were 
categorized as cardiovascular, cerebrovascular, or renal. Cardiovascular events were defined 
as myocardial infarction, congestive heart failure, arrhythmia, angina pectoris, or significant 
cardiac procedures (including pacemaker implantation, coronary bypass, implantable cardio-
verter defibrillator, stent placement, valve replacement, or balloon pump). Cerebrovascular 
events were defined as strokes. Renal events were defined as chronic renal dialysis (≥40 days) 
or renal transplantation.
Analyses were summarized using descriptive statistics. Mean, standard deviation, me-
dian, minimum, and maximum values were calculated for continuous variables, and percent-
ages were calculated for categorical variables. All data analyses were performed using the 
SAS statistical software system version 9.2 (USA).
RESULTS
As of October 2010, 126 Brazilian patients with known ERT status were enrolled 
in the Fabry Registry (61 males, 65 females). Demographic data are presented in Table 1. 
The majority of the Brazilian patients in the Fabry Registry were Caucasian; 5.7% were 
Afro-Brazilian. The median age at onset of symptoms in females was 11.4 years, compared 
to 9.8 years in males, while the mean age of symptom onset was 13.8 years and 13.4 years 
in females and males, respectively. In both males and females, the median age at diagnosis 
was much later than the age at onset of symptoms, with males being diagnosed at a median 
age of 31.9 years and females at 27.1 years. The median time between the onset of first 
symptoms and diagnosis was 20.3 years in males and 14.3 years in females, and the mean 
time from symptom onset to diagnosis for males and females was similar (20.1 and 19.1 
years, respectively). 
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                                                                                        Total No. of patients enrolled
 Males (61) Females (65)
Ethnicity
   Caucasian  27 (44.3)  41 (63.1) 
   Black 4 (6.6)  2 (3.1) 
   Hispanic   9 (14.8)  14 (21.5) 
   Other 18 (29.5)    7 (10.8) 
   Unknown/missing 3 (4.9)  1 (1.5) 
Age as of October 2010 (years)
   N 61 65
   Mean (SD) 39.4 (14.70) 36.5 (16.10)
       Median (min, max)     38.1 (9.1, 77.6)      34.4 (8.9, 74.3)
   Age category (years)
      0 - <10 1 (1.6) 1 (1.5) 
      ≥10 - <20 6 (9.8) 11 (16.9) 
      ≥20 - <30   7 (11.5) 16 (24.6) 
      ≥30 - <40 18 (29.5) 11 (16.9) 
      ≥40 - <50 14 (23.0)   9 (13.8)
      ≥50 15 (24.6) 17 (26.2) 
Age at symptom onset (years)
   N  55 49
   Mean (SD) 13.4 (11.50) 13.8 (9.47)
   Median (min, max)       9.8 (0.8, 61.5)      11.4 (4.1, 49.2)
   Age category (years)
      0 - <10 29 (47.5) 20 (30.8) 
      ≥10 - <20 17 (27.9) 20 (30.8) 
      ≥20 - <30 5 (8.2) 6 (9.2) 
      ≥30 - <40 0 1 (1.5) 
      ≥40 - <50 3 (4.9) 2 (3.1) 
      ≥50 1 (1.6) 0
Age at diagnosis (years)
   N 56 58
   Mean (SD) 31.5 (14.11) 30.5 (15.80)
   Median (min, max)     31.9 (2.2, 62.3)      27.1 (5.0, 72.6)
   Age category (years)
      0 - <10 3 (4.9)  4 (6.2) 
      ≥10 - <20   8 (13.1)  14 (21.5) 
      ≥20 - <30 15 (24.6)  15 (23.1) 
      ≥30 - <40 15 (24.6)    7 (10.8) 
      ≥40 - <50   9 (14.8)  11 (16.9) 
      ≥50 6 (9.8)    7 (10.8) 
Time from symptom onset to diagnosis (years)
   N 48 44
   Mean (SD) 20.1 (13.59)  19.1 (14.84)
   Median (min, max)   20.3 (0.0, 50)   14.3 (0.0, 65)
Table 1. Demographic characteristics of Brazilian Fabry Registry patients.
SD = standard deviation; min = minimum; max = maximum.
A summary of Fabry symptom onset by organ system among male and female patients 
is provided in Figure 1. Neurologic pain was the presenting symptom most frequently reported 
by both genders (80% of males and 62% of females), followed by dermatological findings, 
which were reported in approximately 14% of males and 3% of females.
The age at which Brazilian patients in the Registry first reported a clinical event is 
presented in Table 2. Male patients were more likely to report a clinical event compared to 
females. Renal events were the most common clinical events reported in males (17 patients), 
first occurring at a median age of 38.0 years, while cardiac events were the most common 
events in females (6 patients), occurring at a median age of 44.2 years. 
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                                                             Total No. of patients with a clinical event during the period
 Males (61) Females (65)
Patients reporting renal event during natural history period 
   Age at first renal event (years)
      N 17 1
      Mean (SD) 37.9 (12.02) 37.4 (-)
      Median (range)        38.0 (19.2, 66.4) 37.4 (37.4, 37.4)
Patients reporting cardiovascular event during natural history period
   Age at first cardiovascular event (years)
      N 9  6
      Mean (SD) 46.9 (14.88) 42.7 (10.04)
      Median (range)        44.2 (19.8, 72.6)        44.2 (24.2, 54.1)
Patients reporting cerebrovascular event during natural history period  
   Age at first cerebrovascular event (years)
      N 6  3
      Mean (SD) 44.4 (14.79)  40.1 (8.42) 
      Median (range)        40.4 (32.0, 73.6)         42.3 (30.8, 47.2)
Figure 1. Summary of presenting symptoms at enrollment by organ system. Data are expressed as percentages of 
patients who reported the indicated symptoms at the time of enrollment. Numbers above the bars indicate the number 
of patients in each category. Neuro = neurologic pain; Cerebro = cerebrovascular; Ophthal = ophthalmological; 
Cardio = cardiovascular; Gastro = gastrointestinal; Derm = dermatological.
Table 2. Summary of clinical events (renal, cardiovascular, or cerebrovascular) and age at first clinical event 
during natural history period.
SD = standard deviation.
DISCUSSION
We analyzed the Fabry Registry data of patients enrolled in Brazil to characterize the 
demographic and baseline clinical characteristics of this patient population. In general, it ap-
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pears that FD is less prevalent in the Afro-Brazilian population compared to other ethnicities. 
Wilcox et al. (2008) previously reported that 1.5% of the overall Fabry Registry population 
was Afro-Brazilian, and in the present analyses, only 5.7% (6 of 126 patients) of Brazilian 
Registry patients was Afro-Brazilian, despite the fact that in Brazil, 50.6% of the population is 
Afro-Brazilian (www.brasil.gov.br/sobre/geografia/populacao/etnias).
The results of the present analyses indicate that Brazilian patients were frequently not 
diagnosed with FD until many years after the onset of symptoms. The median time between the 
onset of symptoms and diagnosis in this population was 20.3 years for males and 14.3 years for 
females, which is longer than that previously reported for the overall Fabry Registry population 
(11 years for males and 11.4 years for females) (Wilcox et al., 2008). Eighty percent of Brazilian 
males and 63% of Brazilian females reported neurological pain as the presenting symptom, which 
is higher than the rates reported for the overall Registry population (63% of males and 43% of 
females) (Wilcox et al., 2008). It is possible that patients with more severe disease tend to visit 
their doctors and have their assessments reported more often than patients with milder disease 
do. Further investigations will be needed to determine whether FD severity in Brazilian patients 
differs compared to patients in the rest of the world. In addition, an important consideration in 
interpreting the data presented in this study is the voluntary and observational nature of the Fabry 
Registry; therefore, it may also be that the Brazilian sites are more likely to assess and report 
neurological pain data than the general Registry population. As this is our first report of Brazilian 
demographic data, more studies on FD in this population are needed to confirm these hypotheses.
Cardiac events were the most common type of event in Brazilian women. Renal events 
were the most common type of clinical event in Brazilian men, which differs from what is ob-
served in the Fabry Registry as a whole, and is likely due to the small sample size of Brazilian 
male patients. Overall, cardiac events are the most common type of event reported in Fabry 
Registry men and women (Eng et al., 2007; Wilcox et al., 2008). 
Physicians are encouraged to collaborate, share observations, and generate hypoth-
eses for evaluation, as well as assist in the collection of clinical data for the Fabry Registry 
in an effort to guide and assess future therapeutic interventions. A better understanding of the 
natural history of clinical manifestations of FD via the Registry may provide valuable infor-
mation about which patients may be at greatest risk. Such information can raise awareness of 
FD among the Brazilian medical community and highlight the importance of improved moni-
toring and management options.
FD is treatable, and earlier diagnosis will allow for prompt initiation of appropriate 
treatment. In turn, this may avert irreversible organ damage that could develop during the time 
between symptom onset and diagnosis. The Brazilian medical community should be aware of 
the natural history of FD in order to establish the diagnosis during the early stages of disease 
progression, before the development of severe renal and/or cardiac complications. 
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